Could Alnylam Pharmaceuticals, Inc. (ALNY) See a Reversal After Breaking Its 52-Week High?

March 20, 2018 - By wolcottdaily

Investors sentiment decreased to 0.92 in 2017 Q3. Its down 0.60, from 1.52 in 2017Q2. It turned negative, as 30 investors sold Alnylam Pharmaceuticals, Inc. shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported.
Grp One Trading L P holds 68,743 shares or 0.07% of its portfolio. Glenmede Na reported 175 shares. World Asset Management holds 3,485 shares or 0.01% of its portfolio. Canada Pension Plan Inv Board has 0.03% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 118,010 shares. Pnc Financial Grp Inc holds 8,799 shares. Lpl Fincl Ltd has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,818 shares. First L P stated it has 0.24% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Pacad holds 2,400 shares or 0.06% of its portfolio. Quantitative Invest Management Ltd Liability owns 4,900 shares for 0.01% of their portfolio. Rock Springs Capital Mgmt Ltd Partnership stated it has 105,000 shares or 0.57% of all its holdings. Lmr Prns Llp holds 0.64% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 50,588 shares. Broadfin Cap has 1.29% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 137,900 are owned by Swiss State Bank. Commonwealth Equity owns 7,032 shares. Orbimed Ltd Liability Corporation has invested 1.22% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since October 2, 2017, it had 0 insider purchases, and 9 selling transactions for $47.49 million activity. 85,316 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $10.66 million were sold by Greene Barry E. SHARP PHILIP A also sold $2.24M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, March 13. Another trade for 36,745 shares valued at $4.84M was made by Mason Michael on Thursday, January 4. The insider KEATING LAURIE sold 20,000 shares worth $2.90M. 88,554 shares were sold by Vaishnaw Akshay, worth $12.67 million on Wednesday, March 14. SCHIMMEL PAUL sold 27,823 shares worth $4.17 million.

The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week high and has $157.46 target or 3.00 % above today’s $152.87 share price. The 5 months bullish chart indicates low risk for the $15.24 billion company. The 1-year high was reported on Mar, 20 by If the $157.46 price target is reached, the company will be worth $457.23M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 4.31% or $6.31 during the last trading session, reaching $152.87. About 280,075 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since March 20, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 4. They expect $-1.48 earnings per share, down 18.40 % or $0.23 from last year’s $-1.25 per share. After $-1.48 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals has $220 highest and $34 lowest target. $123.95’s average target is -18.92% below currents $152.87 stock price. Alnylam Pharmaceuticals had 99 analyst reports since August 7, 2015 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Monday, March 12 report. FBR Capital maintained the stock with “Outperform” rating in Thursday, October 6 report. The stock has “Hold” rating by Stifel Nicolaus on Friday, August 11. The company was maintained on Tuesday, February 16 by Leerink Swann. The firm has “Equal-Weight” rating given on Thursday, October 6 by Barclays Capital. Needham maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, September 21 with “Buy” rating. The firm earned “Overweight” rating on Tuesday, August 2 by Morgan Stanley. The company was maintained on Wednesday, November 30 by Chardan Capital Markets. The firm has “Neutral” rating by JP Morgan given on Thursday, October 6. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Neutral” rating by JP Morgan on Friday, August 7.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $15.24 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.